A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061

NCT07241910 ↗

Phase 1 Recruiting 40 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single-ascending dose study in healthy subjects to evaluate the safety, tolerability, PK, and PD of SYH2061.

Timeline

Start: 2025-12-23
Primary completion: 2026-11-24
Completion: 2027-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SYH2061	Unknown	—	Subcutaneous

Indications

No indication recorded.